SCP
ACHL

Sender Company & Partners’s Achilles Therapeutics ACHL Stock Holding History

Sender Company & Partners’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,690
Closed -$139K – 112
2021
Q4 		$139K Buy
+27,690
New +$168K 0.07% 94

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sender Company & Partners's ACHL Position: Q1 2022 in Review

Sender Company & Partners sold out of Achilles Therapeutics (ACHL) in Q1 2022, closing a stake of 27,690 shares — an estimated $139K sold.

Sender Company & Partners first reported a position in ACHL in Q4 2021 and held it in 1 quarter. The position peaked at $139K in Q4 2021. 25 funds tracked by Wall St. Rank hold ACHL as of Q1 2022.

  • Sender Company & Partners reported no remaining Achilles Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 27,690 Achilles Therapeutics shares in Q1 2022, an estimated $139K.
  • Sender Company & Partners first reported a position in Achilles Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Achilles Therapeutics position peaked at $139K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.